OncoMatch/Clinical Trials/NCT06245889
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Is NCT06245889 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for triple negative breast cancer.
Treatment: Paclitaxel · Carboplatin · Pembrolizumab · Doxorubicin · Cyclophosphamide · Olaparib · Capecitabine — Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will be performed after treatment completion. Patients with complete clinical response will proceed to surgery. Patients with clinical residual disease will complete neoadjuvant rescue with 4 cycles of doxorubicin/cyclophosphamide prior to surgery. If residual disease identified after surgery, adjuvant therapy to be determined by the treating oncologist (may include doxorubicin/cyclophosphamide/pembrolizumab, capecitabine etc).
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Allowed: ESR1 expression up to and including 10%
estrogen receptor (ER) up to and including 10% is eligible
Allowed: PR (PGR) expression up to and including 10%
progesterone receptor (PR) up to and including 10% is eligible
Disease stage
Required: Stage II, III
Stage II-III TNBC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: taxane (paclitaxel)
Previous treatment with paclitaxel
Cannot have received: platinum-based chemotherapy (carboplatin)
Previous treatment with carboplatin
Cannot have received: checkpoint inhibitor
Previous treatment with immune checkpoint inhibitors
Lab requirements
Blood counts
Adequate marrow function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify